BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32287077)

  • 1. Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified.
    Cho I; Yoon N; Hyeon J; Sim J; Yoo HY; Kim SJ; Kim WS; Ko YH
    Appl Immunohistochem Mol Morphol; 2020; 28(10):731-740. PubMed ID: 32287077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
    Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
    Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.
    Schrader AMR; de Groen RAL; Willemze R; Jansen PM; Quint KD; van Wezel T; van Eijk R; Ruano D; Tensen CP; Hauben E; Woei-A-Jin FJSH; Busschots AM; van den Berg A; Diepstra A; Vermeer MH; Vermaat JSP
    Virchows Arch; 2022 Mar; 480(3):667-675. PubMed ID: 35028710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological Analysis of 320 Cases of Diffuse Large B-cell Lymphoma Using the Hans Classifier.
    Ichiki A; Carreras J; Miyaoka M; Kikuti YY; Jibiki T; Tazume K; Watanabe S; Sasao T; Obayashi Y; Onizuka M; Ohmachi K; Yoshiba F; Shirasugi Y; Ogawa Y; Kawada H; Nakamura N; Ando K
    J Clin Exp Hematop; 2017; 57(2):54-63. PubMed ID: 29021515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia.
    Phang KC; Akhter A; Tizen NMS; Rahman FA; Zahratul Azma R; Elyamany G; Shabani-Rad MT; Masir N; Mansoor A
    J Clin Pathol; 2018 Mar; 71(3):215-220. PubMed ID: 28775174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series.
    Zamò A; Gerhard-Hartmann E; Ott G; Anagnostopoulos I; Scott DW; Rosenwald A; Rauert-Wunderlich H
    Virchows Arch; 2022 Dec; 481(6):935-943. PubMed ID: 36219238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature.
    Lee J; Hue SS; Ko SQ; Tan SY; Liu X; Girard LP; Chan EHL; De Mel S; Jeyasekharan A; Chee YL; Koh LP; Poon LM
    Expert Rev Hematol; 2019 Dec; 12(12):1095-1105. PubMed ID: 31592693
    [No Abstract]   [Full Text] [Related]  

  • 8. CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.
    Cozzolino I; Varone V; Picardi M; Baldi C; Memoli D; Ciancia G; Selleri C; De Rosa G; Vetrani A; Zeppa P
    Cancer Cytopathol; 2016 Feb; 124(2):135-43. PubMed ID: 26414904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary central nervous system lymphoma: Comprehension of cell-of-origin subtypes.
    Rao S; Epari S; Shet TM; Gujral S; Jain H; Bagal B; Senagar M; Shetty P; Moiyadi A; Goda JS; Gupta T
    Indian J Pathol Microbiol; 2023; 66(3):549-555. PubMed ID: 37530337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphoma-a feasibility study using full slide staining.
    Reinke S; Richter J; Fend F; Feller A; Hansmann ML; Hüttl K; Oschlies I; Ott G; Möller P; Rosenwald A; Stein H; Altenbuchinger M; Spang R; Klapper W
    Virchows Arch; 2018 Sep; 473(3):341-349. PubMed ID: 29730836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic Value of Morphology and Hans Classification in Diffuse Large B Cell Lymphoma].
    Wang KL; Chen C; Shi PF; Yu JH; Tan JF; Qian SX; Gao DQ; Chen K; Liu LR; Xie YP; Xu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1079-1085. PubMed ID: 30111411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms.
    Hwang HS; Yoon DH; Hong JY; Park CS; Lee YS; Ko YH; Kim SJ; Kim WS; Suh C; Huh J
    Ann Hematol; 2018 Dec; 97(12):2363-2372. PubMed ID: 30069703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse large B-cell lymphoma with composite germinal center and non-germinal center types: A report of two cases.
    Sugitani A; Fukuhara S; Shibata M; Ichihara R; Furukawa H; Maeshima AM
    J Clin Exp Hematop; 2023 Sep; 63(3):181-186. PubMed ID: 37518270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.
    Bhattacharyya I; Chehal HK; Cohen DM; Al-Quran SZ
    Head Neck Pathol; 2010 Sep; 4(3):181-91. PubMed ID: 20533006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.
    Abdulla M; Hollander P; Pandzic T; Mansouri L; Ednersson SB; Andersson PO; Hultdin M; Fors M; Erlanson M; Degerman S; Petersen HM; Asmar F; Grønbaek K; Enblad G; Cavelier L; Rosenquist R; Amini RM
    Am J Hematol; 2020 Jan; 95(1):57-67. PubMed ID: 31659781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.
    Borovecki A; Korać P; Nola M; Ivanković D; Jaksić B; Dominis M
    Croat Med J; 2008 Oct; 49(5):625-35. PubMed ID: 18925696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of GCET1, HGAL (GCET2), and LMO2 in the Determination of Germinal Center Phenotype in Diffuse Large B-cell Lymphoma.
    Berker N; Yeğen G; Özlük Y; Doğan Ö
    Turk J Haematol; 2023 Aug; 40(3):162-173. PubMed ID: 37519110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma.
    Lu TX; Miao Y; Wu JZ; Gong QX; Liang JH; Wang Z; Wang L; Fan L; Hua D; Chen YY; Xu W; Zhang ZH; Li JY
    Sci Rep; 2016 Feb; 6():20465. PubMed ID: 26857366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
    Choi WW; Weisenburger DD; Greiner TC; Piris MA; Banham AH; Delabie J; Braziel RM; Geng H; Iqbal J; Lenz G; Vose JM; Hans CP; Fu K; Smith LM; Li M; Liu Z; Gascoyne RD; Rosenwald A; Ott G; Rimsza LM; Campo E; Jaffe ES; Jaye DL; Staudt LM; Chan WC
    Clin Cancer Res; 2009 Sep; 15(17):5494-502. PubMed ID: 19706817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.